Within this environment, MTHFD2 attracted considerable interest for the first time, and indeed, a large number of studies have confirmed the transcriptional upregulation of MTHFD2 across cancer types: breast [27,28], AML [29], glioblastoma [30], and kidney cancer [31], among others. This evidence concerns the gene MTHFD2 and glioblastoma.